Media

In an interview published by Techcouver, CEO Dan Wattier discusses how 3C Therapeutics is working with Variational AI to explore generative AI for the design of new cancer therapies.

BioCentury’s Emerging Company Profile covers 3C’s modular approach to degrader-antibody conjugates.

The collaboration applies Variational AI’s Enki platform to ligand design for 3C Therapeutics’ TriCore DAC platform, with support from Innovate BC’s Integrated Marketplace program.